What is it about marijuana that makes it more frightening to the federal govt. than morphine?

RainDog

(1000+ posts) Send PM | Profile | Ignore

Thu Jul-14-11 07:55 PM
Original message

What is it about marijuana that makes it more frightening to the federal govt. than morphine?

http://www.latimes.com/news/opinion/opinionla/la-ed-marijuana-20110713,0,3089477.story

What is it that makes marijuana more frightening to the federal government than cocaine or morphine? The Drug Enforcement Administration has steadfastly, over decades, listed marijuana as a Schedule I drug, meaning that it has no medical value and that the potential for abuse is high. Cocaine and morphine, far more dangerous and habit-forming, are listed as Schedule II because they have some medical value.

Last week the DEA ruled once again, a decade after it made the same decision, that marijuana is a potentially dangerous drug without known medical benefits. During the intervening 10 years, though, nine more states passed medical marijuana laws, bringing the total to 17. Two years ago, the American Medical Assn. recommended changing the classification of marijuana to Schedule II, which would make it easier for researchers to obtain the drug for medical studies.

In March, the National Cancer Institute reported: "The potential benefits of medicinal cannabis for people living with cancer include antiemetic effects, appetite stimulation, pain relief and improved sleep." However, it stopped short of endorsing marijuana as a medical treatment, concluding that there was too little evidence.

The cancer institute and the DEA are right that there's not enough scientific evidence about the medical uses of cannabis. But whose fault is that? The biggest reason there is so little proof about marijuana, one way or the other, is that the federal government is paranoid about legitimate research on the drug and has refused to relist it as Schedule II. The few and scattered studies that have been completed, in this country and around the world, have not proved marijuana's potential benefits, but by and large, they have produced some promising findings. In the late 1990s, both the New England Journal of Medicine and the Institute of Medicine, part of the National Academy of Sciences, suggested that marijuana appeared to have some medical uses and recommended more research.

I would beg to differ with this editorial on one issue. There have, in fact, been tens of thousands of studies done related to marijuana.

As noted here:

"Marijuana is already the most studied plant on Earth, and is arguably one of the most investigated therapeutically active substances known to man. To date, there are now over 20,000 published studies or reviews in the scientific literature pertaining to marijuana and its active compounds. That total includes over 2,700 separate papers published on cannabis in 2009 and another 900 published just this year alone (according to a key word search on the search engine PubMed).

And what have we learned from these 20,000+ studies? Not surprisingly, quite a lot. For starters, we know that cannabis and its active constituents are uniquely safe and effective as therapeutic compounds. Unlike most prescription or over-the-counter medications, cannabinoids are virtually non-toxic to health cells or organs, and they are incapable of causing the user to experience a fatal overdose. Unlike opiates, cannabinoids do not depress the central nervous system, and as a result they possess a virtually unparalleled safety profile. In fact, a 2008 meta-analysis published in the Journal of the Canadian Medical Association (CMAJ) reported that cannabis-based drugs were associated with virtually no serious adverse side effects in over 30 years of investigative use.

We also know that the cannabis plant contains in excess of 60 active compounds that likely possess distinctive therapeutic properties. These include THC, THCV, CBD, THCA, CBC, and CBG, among others. In fact, a recent review by Raphael Mechoulam and colleagues identifies nearly 30 separate therapeutic effects — including anti-cancer properties, anti-diabetic properties, neuroprotection, and anti-stroke properties — in cannabinoids other than THC. Most recently, a review by researchers in Germany reported that since 2005 there have been 37 controlled studies assessing the safety and efficacy of cannabinoids, involved a total of 2,563 subjects. By contrast, most FDA-approved drugs go through far fewer trials involving far fewer subjects.

Finally, we know that Western civilization has been using cannabis as a therapeutic agent or recreational intoxicant for thousands of years with relatively few adverse consequences — either to the individual user or to society. In fact, no less than the World Health Organization commissioned a team of experts to compare the health and societal consequences of marijuana use compared to other drugs, including alcohol, nicotine, and opiates. After quantifying the harms associated with both drugs, the researchers concluded: “Overall, most of these risks (associated with marijuana) are small to moderate in size. In aggregate they are unlikely to produce public health problems comparable in scale to those currently produced by alcohol and tobacco. On existing patterns of use, cannabis poses a much less serious public health problem than is currently posed by alcohol and tobacco in Western societies.”

http://blog.norml.org/2010/07/01/theres-been-over-20000-studies-on-marijuana-what-is-it-that-scientists-do-not-yet-know/